PDFF Biomarker Ctte: Difference between revisions
Jump to navigation
Jump to search
| Line 12: | Line 12: | ||
<br />Notes are posted after they are approved by the PDFF BC during the following t-con | <br />Notes are posted after they are approved by the PDFF BC during the following t-con | ||
*[[Media:2021_01-07_QIBA_PDFF_BC_Call_Summary-FINAL.pdf|January 7, 2021]] | |||
*[[Media:2020_11-05_QIBA_PDFF_BC_Call_Summary-FINAL.pdf|November 5, 2020]] | *[[Media:2020_11-05_QIBA_PDFF_BC_Call_Summary-FINAL.pdf|November 5, 2020]] | ||
*[[Media:2020_07-02_QIBA_PDFF_BC_Call_Summary-FINAL.pdf|July 2, 2020]] | *[[Media:2020_07-02_QIBA_PDFF_BC_Call_Summary-FINAL.pdf|July 2, 2020]] | ||
'''''[[PDFF Biomarker Committee Call Summaries Archive]]''''' | '''''[[PDFF Biomarker Committee Call Summaries Archive]]''''' | ||
Revision as of 22:38, 4 February 2021
- Co-chairs: Scott Reeder, MD, PhD, Takeshi Yokoo, MD, PhD
- RSNA Staff Support: Susan Stanfa
The PDFF Biomarker Committee seeks to develop a quantitative Profile for PDFF.
Meetings
Approved call summaries:
Notes are posted after they are approved by the PDFF BC during the following t-con
PDFF Biomarker Committee Call Summaries Archive